Tango Therapeutics Shares Fall Despite Positive Pancreatic Cancer Trial Data

Key Facts

1Tango Therapeutics reported an 82% response rate in pancreatic cancer trials.

2The company is preparing for a randomized registrational study in early 2027.

Tango Therapeutics reported an 82% response rate in clinical trials for its pancreatic cancer drug candidate. According to Benzinga, the company is preparing to initiate a randomized registrational study in early 2027 as part of its oncology development pipeline.

Shares of TNGX traded lower following the announcement, reaching a session low of $25.94 on October 22, 2026. The stock closed at $27.93 on October 22, 2026, as investors reacted to the clinical data and the projected timeline for the next phase of registrational studies.